BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/24/2022 10:56:44 AM | Browse: 384 | Download: 718
 |
Received |
|
2022-03-13 00:44 |
|
Peer-Review Started |
|
2022-03-13 00:46 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-08 09:06 |
|
Revised |
|
2022-05-14 13:01 |
|
Second Decision |
|
2022-08-09 02:55 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-08-11 03:56 |
|
Articles in Press |
|
2022-08-11 03:56 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-08-04 04:37 |
|
Typeset the Manuscript |
|
2022-08-24 03:32 |
|
Publish the Manuscript Online |
|
2022-09-24 10:56 |
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Review |
| Article Title |
Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Dimitrina Miteva, Monika Peshevska-Sekulovska, Violeta Snegarova, Hristiana Batselova, Radostina Alexandrova and Tsvetelina Velikova |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| None |
|
|
| Corresponding Author |
Tsvetelina Velikova, MD, PhD, Assistant Professor, Department of Clinical Immunology, University Hospital Lozenetz, Kozyak 1 Street, Sofia 1407, Bulgaria. tsvelikova@medfac.mu-sofia.bg |
| Key Words |
SARS-CoV-2; COVID-19 vaccine; Mucosal immunity; Intranasal vaccination; Oral vaccines; Resident memory T cells; Vaccine safety; Vaxart; OraPro-COVID-19 vaccine; RPS-vector system platform |
| Core Tip |
Oral or nasal vaccination against coronavirus disease 2019 (COVID-19) would stimulate both the humoral and cellular immune responses and may exert many socioeconomic benefits. Mucosal vaccines are promising for preventing infections and reducing the transmission, morbidity and mortality of COVID-19. Mucosal vaccination may be used prophylactically in human populations at high risk for severe acute respiratory syndrome coronavirus 2. Currently, only a limited number of oral vaccines are approved for human use, and some others are included in preclinical and clinical trials to validate their efficacy and safety. |
| Publish Date |
2022-09-24 10:56 |
| Citation |
Miteva D, Peshevska-Sekulovska M, Snegarova V, Batselova H, Alexandrova R, Velikova T. Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic. World J Virol 2022; 11(5): 221-236 |
| URL |
https://www.wjgnet.com/2220-3249/full/v11/i5/221.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v11.i5.221 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
